Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Regular moderate drinker (2-3 drinks, weekly): Your healing timeline extends
These drugs are becoming more common
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
CoQ10 at 100 to 200 mg daily may benefit some users, though evidence is mixed
US$ 20.01
US$ 24.21
US$ 20.22
US$ 29.43
